Biotest AG: Annual general meeting approves payout of dividend
News: Biotest AG / Key word(s): AGM/EGM
Biotest AG: Annual general meeting approves payout of dividend - Dividend payout of EUR 0.02 per ordinary share and EUR 0.04 per preference share Dreieich/ Frankfurt a. M., 12 May 2016. At the annual general meeting (AGM) held on 12 May 2016 in Frankfurt/ Main, shareholders of Biotest AG approved the payment of a dividend. With 74,4 percent of the ordinary share capital represented at the meeting, a payment of EUR 0.02 per ordinary share and EUR 0.04 per preference share was resolved with a high degree of approval. The overall dividend payment will amount to EUR 1.2 million. The annual general meeting, with 257 shareholders present, formally discharged the members of the Management Board and Supervisory Board for financial year 2015. The full text of the speech given by the CEO of Biotest AG, Dr. Bernhard Ehmer, at the AGM is available at: http://www.biotest.com/de/en/investor_relations/shareholders_meeting.cfm About Biotest IR contact PR contact Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de Ordinary shares: securities' ID No. 522720; ISIN DE0005227201 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. 2016-05-12 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English | |
Company: | Biotest AG | |
Landsteinerstraße 5 | ||
63303 Dreieich | ||
Germany | ||
Phone: | 0 61 03 - 8 01-0 | |
Fax: | 0 61 03 - 8 01-150 | |
E-mail: | investor_relations@biotest.de | |
Internet: | http://www.biotest.de | |
ISIN: | DE0005227235, DE0005227201 | |
WKN: | 522723, 522720 | |
Indices: | SDAX | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart | |
End of News | DGAP News Service |